<DOC>
	<DOCNO>NCT01181258</DOCNO>
	<brief_summary>In study investigator investigate cell therapy strategy could harness allogeneic effector potentially mediate anti-lymphoma effect . The investigator design novel lymphodepleting condition regimen follow infusion donor-derived natural killer ( NK ) cell interleukin-2 ( IL-2 ) patient refractory lymphoid malignancy .</brief_summary>
	<brief_title>Penostatin , Rituximab Ontak Allogeneic Natural Killer ( NK ) Cells Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>This single center phase II trial designate expand donor NK cell induce remission patient refractory non-Hodgkin lymphoma ( NHL ) chronic lymphocytic leukemia ( CLL ) use chemotherapy follow haploidentical NK cell IL2 . Primary Objective evaluate objective response rate ( PR+CR ) 2 month post haploidentical NK cell infusion patient refractory Non Hodgkin 's Lymphoma ( NHL ) chronic lymphocytic leukemia ( CLL ) . Secondary Objective 1 ) evaluate safety tolerability lymphodepleting chemotherapy , rituximab , methylprednisone determine incidence serious adverse event ; 2 ) evaluate vivo expansion allogeneic donor NK cell day 14 ; 3 ) determine time progression Exploratory Objective 1 ) correlate clinical response frequency peripheral blood T reg cell chemotherapy ; 2 ) correlate clinical response donor KIR-B-content score determine genotype ; 3 ) monitor phenotypic functional characteristic natural killer cell regulatory T cell vivo ; 4 ) correlate clinical response donor FcR polymorphism . - Pre-NK cell infusion chemotherapeutic regimen consist 1 ) Rituximab 375mg/m2 IV weekly x 4 , start day -7 ; 2 ) Fludarabine 25 mg/m2 IV day -6 day -2 ; 3 ) Cyclophosphamide 60mg/kg IV day -5 ; 4 ) Methylprednisolone 1 mg/kg day -2 day +9 . - NK cell infusion use IL2 activate donor NK cell 1.5 8 x 107 cells/kg IV day 0 - IL2 SC 9 million IU every day x 6 dos 2 week begin 1 24 hour NK cell infusion . If weight &lt; 45 kilogram , give IL-2 5 million units/m2 schedule Accrual Goal : Up 17 patient enrol</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients age diagnosis : Relapsed/refractory lymphoma ( B cell nonHodgkin ) lack objective response least two prior chemotherapy regimen Relapsed chronic lymphocytic leukemia high risk feature : lack objective response relapse within 6 month follow nucleosideanalogue base chemotherapy regimen patient 17p deletion CLL lack objective response least 1 precede chemotherapy regimen Available related HLA haploidentical NK cell donor least Class I serologic type A &amp; B locus ( age 1275 year ) Karnofsky &gt; 70 % patient 16 year old Lansky play score &gt; 50 patient 16 year age Measurable disease base modify Response Evaluation Criteria Solid Tumors ( RECIST ) Have acceptable organ function define within 28 day enrollment : Hematologic : platelet ≥ 80,000 x 10^9/L ; hemoglobin ≥ 9 g/dL , unsupported transfusion within 7 day ; absolute neutrophile count ( ANC ) ≥ 1000 x 10^9/L , unsupported Granulocyte colonystimulating factor ( GCSF ) GranulocyteMacrophage Colony Stimulating Factor ( GMCSF ) 10 day Neulasta 21 day hematologic requirement waive patient inadequate count due know bone marrow involvement disease otherwise eligible Renal : calculated glomerular filtration rate ( GFR ) &gt; 50 ml/min Hepatic : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 x upper limit normal total bilirubin ≤3 mg/dl hepatic requirement waive patient know disease involvement liver otherwise eligible Pulmonary function : &gt; 40 % correct Carbon Monoxide Diffusing Capacity ( DLCO ) Forced expiratory volume one second ( FEV1 ) ( oxygen saturation [ &gt; 92 % ] use child pulmonary function test ( PFT 's ) obtain ) Cardiac : symptom uncontrolled cardiac disease , leave ventricular ejection fraction ≥ 40 % Able prednisone immunosuppressive medication least 3 day prior Day 0 ( exclude denileukin diftitox premedications ) Sexually active woman childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . Voluntary write consent Pregnant lactating . The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 14 day prior enrollment rule pregnancy . Women childbearing age must use appropriate contraceptive method . Active central nervous system ( CNS ) lymphoma/leukemia Patients prior CNS involvement eligible provide treated remission . Active serious infection ( pulmonary infiltrates lesion allow appropriate diagnostic test negative infection appropriate therapy initiate probable infection ) Pleural effusion large enough detectable chest xray ( CXR ) Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology Active concurrent malignancy ( except skin cancer ) EpsteinBarr virus ( EBV ) posttransplant lymphoproliferative disorder Positive HBsAg . If HBcAb positive , Hepatitis B DNA PCR evaluate . Positive anti HBcAb undetectable viral load exclude patient . Any investigational therapy past 30 day Patients follow allogeneic stem cell transplantation eligible absence graft versus host disease immunosuppression least 30 day Known allergy study agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>related HLA-haploidentical donor</keyword>
</DOC>